These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 19948947)

  • 1. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
    Farid NA; Kurihara A; Wrighton SA
    J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
    Hagihara K; Kazui M; Kurihara A; Yoshiike M; Honda K; Okazaki O; Farid NA; Ikeda T
    Drug Metab Dispos; 2009 Nov; 37(11):2145-52. PubMed ID: 19704027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
    Abell LM; Liu EC
    J Pharmacol Exp Ther; 2011 Nov; 339(2):589-96. PubMed ID: 21828263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
    Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
    Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
    Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
    J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
    Varenhorst C; James S; Erlinge D; Brandt JT; Braun OO; Man M; Siegbahn A; Walker J; Wallentin L; Winters KJ; Close SL
    Eur Heart J; 2009 Jul; 30(14):1744-52. PubMed ID: 19429918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
    Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Takahashi M; Kurihara A; Okazaki O; Farid NA; Ikeda T
    Xenobiotica; 2009 Mar; 39(3):218-26. PubMed ID: 19280520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the metabolism of clopidogrel and prasugrel.
    Laizure SC; Parker RB
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1417-24. PubMed ID: 20839914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
    Nishiya Y; Hagihara K; Kurihara A; Okudaira N; Farid NA; Okazaki O; Ikeda T
    Xenobiotica; 2009 Nov; 39(11):836-43. PubMed ID: 19845434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
    Wynn RL
    Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
    Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
    Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T
    Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic differences of current thienopyridine antiplatelet agents.
    Fareed J; Jeske W; Thethi I
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):307-17. PubMed ID: 23289968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
    Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
    Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
    Tantry US; Jeong YH; Navarese EP; Kubica J; Gurbel PA
    Expert Rev Cardiovasc Ther; 2013 Apr; 11(4):447-62. PubMed ID: 23570358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias WL; Braunwald E; Sabatine MS
    Circulation; 2009 May; 119(19):2553-60. PubMed ID: 19414633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
    Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS
    Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.